Glatiramer acetate 3X per week

G
Teva announced yesterday that a new version of Copaxone met its goals in a late-stage clinical trial. MSers who took the newer version of glatiramer acetate were ~34% less likely to have a relapse of their symptoms over the course of a year compared to MSers who took placebo. Copaxone is injected once a day, and the new version needs to be taken only 3x a week. Teva said the late-stage trial involved around 1,400 MSers. 


About the author

Prof G

Professor of Neurology, Barts & The London. MS & Preventive Neurology thinker, blogger, runner, vegetable gardener, husband, father, cook and wine & food lover.

3 comments

  • Oh, so they are trying to sell the old stuff, with some "modifications" for PR reasons methinks. I wonder if anyone is going to take injectables which are not terrifically effective either once oral medications get off the ground.

  • maybe they wiill come up with a X1 study in a decade or so once the liofe of the X3 runs out
    🙂

By Prof G

Translate

Categories

Recent Posts

Recent Comments

Archives